Skip to main content
Equibles
EW logo

EW · Edwards Lifesciences Corp · Metrics

Track EW — free

Use EW with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research EW.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$107.15 +1.35 (+1.28%) At close · Nov 13 Play latest call Q2 2026 earnings call transcript
S&P 500 member Russell 1000 member Rebalance outlook locked
Market Cap
$61.61B
Shares
575.00M
Volume · Nov 13 3.82M Avg daily vol (3M) 3.81M

EW metrics

102 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$107.15
Market cap
$61.61B

Price action

23 metrics
Price change (1W)
+4.9%
Price change (30D)
+21.6%
Price change (3M)
+17.0%
Price change (6M)
+31.7%
Price change (YTD)
+25.7%
Price change (1Y)
+24.4%
Trailing year
Price change (5Y)
-7.6%
52-week high
$107.15
52-week low
$75.87
Change from 52-week high
+0.0%
Change from 52-week low
+41.2%
Annualized volatility
25.6%
Annualized volatility (3M)
24.9%
Implied volatility (30D)
26.1%
IV rank (1Y)
19.3
IV percentile (1Y)
19.9
Beta
0.6
RSI (14D)
80.3
Price vs SMA 50
+18.5%
Price vs SMA 200
+24.1%
Avg volume (3M)
3.81M
Relative volume
1.0
Average dollar volume
$347.98M

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
575.00M

Valuation

12 metrics
P / E (TTM)
60.5
Trailing earnings · reciprocal yield 1.7%
PEG ratio
10.1
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
9.2×
reciprocal yield 10.8%
P / book
5.7
reciprocal yield 17.6%
FCF yield
2.3%
TTM · current market cap
Buyback yield
1.2%
P / FCF
43.3
reciprocal yield 2.3%
P / operating cash flow
35.9
reciprocal yield 2.8%
Earnings yield
1.7%

Historical valuation

8 metrics
P / E historical average (3Y)
30.7×
reciprocal yield 3.3%
P / E historical average (5Y)
33.4×
reciprocal yield 3.0%
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
1.2%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-11-04

Profitability

9 metrics
Gross margin
78.0%
Operating margin
21.6%
Trailing 12 months
Net margin
15.4%
Gross profit (TTM)
$5.21B
Operating profit (TTM)
$1.44B
Net income (TTM)
$1.02B
Trailing 12 months
Diluted EPS (TTM)
$1.77
FCF margin
21.3%
Effective tax rate
31.0%

Per share

11 metrics
Revenue per diluted share (TTM)
$11.52
Gross profit per diluted share (TTM)
$8.99
Operating profit per diluted share (TTM)
$2.49
EBITDA per diluted share (TTM)
$2.78
Net income per diluted share (TTM)
$1.77
Operating cash flow per diluted share (TTM)
$2.97
Free cash flow per diluted share (TTM)
$2.46
Capital expenditures per diluted share (TTM)
$0.51
R&D per diluted share (TTM)
$1.88
Stock compensation per diluted share (TTM)
$0.30
Book value per share
$17.80

Growth

11 metrics
Revenue growth YoY
+10.5%
Year over year
Net income growth YoY
+5.6%
Revenue (TTM)
$6.67B
Trailing 12 months
EPS growth YoY
+6.0%
Shares change YoY
-1.4%
Year over year · fewer shares
Revenue CAGR (3Y)
+10.8%
Revenue CAGR (5Y)
+6.7%
EPS CAGR (3Y)
-9.1%
EPS CAGR (5Y)
+7.1%
FCF CAGR (3Y)
+11.1%
FCF CAGR (5Y)
+15.6%

Quality

14 metrics
Return on equity
9.4%
Return on assets
7.2%
Debt / equity
—
Current ratio
4.6
EBITDA (TTM)
$1.61B
Free cash flow (TTM)
$1.42B
Quick ratio
3.9
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$3.11B
Total assets
$14.14B
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$1.72B
Capital expenditures (TTM)
$292.80M
R&D (TTM)
$1.09B
SG&A (TTM)
$2.25B
Stock compensation (TTM)
$172.80M
R&D / revenue
16.3%
Stock compensation / revenue
2.6%

Ownership (13F)

9 metrics
13F filers
1,341
13F filer change QoQ
+43
Institutional ownership
91.3%
Conviction holders (share of 13F filers)
0.8%
Crowding (high-turnover and private-fund holders)
16.6%
Private-fund adviser ownership
16.1%
Active holders' share change QoQ
+1.7%
Holder tenure
17.5
Price vs estimated holder cost
+12.8%

Ownership (registered funds)

1 metrics
Index-fund ownership
20.0%

Short interest

3 metrics
Short interest
1.6%
Latest settlement · 2.8 days to cover
Days to cover
2.8d
Short-squeeze score
47 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$10.89M
Insider-sentiment score
23 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1099800 CUSIP 28176E108 13F (30d) 1090 filings 1004 filers Visit website Investor relations